Cambridge Nutraceuticals is based in Cambridge, UK. It develops and markets supplements scientifically proven to deliver more of the good stuff to you through its brand FutureYou. Its first product – Ateronon Heart Health – gained international fame as ‘The Tomato Pill’ and is designed to protect against cardiovascular disease.
Sales have also been made to many key international territories – in 2015 for example, the Australian regulators approved Ateronon Heart Health for the reduction of oxidised LDL cholesterol. Nevertheless, the primary market to date has been the UK, where Cambridge Nutraceuticals is focussed on the rapid development of its ecommerce business.
In April 2015, Cambridge Nutraceuticals launched Ateronon XY, for men’s health, and Ateronon Active, for sports recovery and joint health. Several new proprietary products with proven bioavailability and efficacy, addressing large markets such as brain health, metabolic syndrome and type 2 diabetes, are also in the pipeline for launch 2015-16.
Ateronon Heart Health is sold as a nutraceutical supplement directly to customers online through FutureYou and via distributors in several overseas markets.
Ateronon Heart Health has been the subject of clinical testing by teams from each of Cambridge and Harvard Universities and is the result of over £12m of development expenditure. Led by serial entrepreneurs Tim Dye and Adam Cleevely, the Company is backed by several of the Cambridge Angels investment group.
Cambridge Nutraceuticals’s product development is supported by a high profile medical board including, among others, Professor Alf Lindberg (former head of R&D at Wyeth and Aventis and former member of the Nobel Committee and Secretary of the Medical Prize), Peter Kirkpatrick FRCS (a leading Cambridge University vascular neurosurgeon) and Dr Andrew Carson FRCGP (a senior NHS General Medical Practitioner).